Mirogabalin
From Wikipedia, the free encyclopedia
 |
|
| Identifiers | |
|---|---|
|
|
| CAS Number | 1138245-21-2  |
| PubChem (CID) | 49802951 |
| ChemSpider | 32701007 |
| Chemical and physical data | |
| Formula | C12H19NO2 |
| Molar mass | 209.285 g/mol |
| 3D model (Jmol) | Interactive image |
|
|
|
|
Mirogabalin (DS-5565) is a drug developed by Daiichi Sankyo and related to drugs such as gabapentin and pregabalin. Similarly to these drugs, mirogabalin binds to the α2δ calcium channels (1 and 2), but with significantly higher potency than pregabalin. It has shown promising results in Phase II clinical trials for the treatment of diabetic peripheral neuropathic pain,[1][2] and is currently in Phase III trials.
See also[edit]
References[edit]
- ^ Vinik, A; Rosenstock, J; Sharma, U; Feins, K; Hsu, C; Merante, D; et al. (Dec 2014). "Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study". Diabetes Care. 37 (12): 3253–61. doi:10.2337/dc14-1044. PMID 25231896.
- ^ Vinik, A; Sharma, U; Feins, K; Hsu, C; Merante, D (2014). "DS-5565 for the Treatment Of Diabetic Peripheral Neuropathic Pain: Randomized, Double-Blind, Placebo- And Active Comparator-Controlled Phase II Study (S20.004)". Neurology. 82 (10): S20.004.
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
